Impact of a Multicenter, Mentored Quality Collaborative on Hospital-Associated Venous Thromboembolism.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 29455231.
- Also identified by DOI 10.12788/jhm.2942.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Reliable prophylaxis of hospitalassociated venous thromboembolism (HA-VTE) is not achieved in many hospitals. Efforts to improve prophylaxis have had uneven results. To reduce HA-VTE with a scalable quality improvement collaborative. A prospective, unblinded, open-intervention study with historical controls. All adult inpatients at 35 community hospitals in California, Arizona, and Nevada. A centrally supported collaborative implementing standardized VTE risk assessment and prophylaxis. Protocols were developed with 9 "pilot" sites, which received individualized mentoring. Finished protocols were disseminated to 26 "spread" sites, which received improvement webinars without mentoring. Active surveillance for real-time correction of suboptimal prophylaxis was funded in pilot sites and encouraged in spread sites. Planning and minimal improvement work began in 2011; most implementation occurred in 2012 and 2013. Rates of per-protocol prophylaxis (at pilot sites), and compliance with The Joint Commission VTE measures (all sites), were monitored starting in January 2012. The International Classification of Diseases, 9th Edition-Clinical Modification codes were used to determine the rates of HA-VTE within 30 days of discharge, heparininduced thrombocytopenia, and anticoagulation adverse events; preimplementation (2011) rates were compared with postimplementation (2014) rates. Protocol-appropriate prophylaxis rates and The Joint Commission measure compliance both reached 97% in 2014, up from 70% to 89% in 2012 and 2013. Five thousand three hundred and seventy HA-VTEs occurred during 1.16 million admissions. Four hundred twenty-eight fewer HA-VTEs occurred in 2014 than in 2011 (relative risk 0.78; 95% confidence interval, 0.73-0.85). HA-VTEs fell more in pilot sites than spread sites (26% vs 20%). The rates of adverse events were reduced or unchanged. Collaborative efforts were associated with improved prophylaxis rates and fewer HA-VTEs.
Medical subject headings
- Inpatients
- Mentors
- Venous Thromboembolism